Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at BTIG Research

Analysts at BTIG Research began coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $42.00 price target on the stock. BTIG Research’s price objective points to a potential upside of 81.43% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on ELVN. HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Robert W. Baird boosted their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $38.25.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $23.15 on Friday. Enliven Therapeutics has a 1 year low of $10.90 and a 1 year high of $30.03. The stock’s fifty day moving average price is $26.56 and its two-hundred day moving average price is $24.16. The company has a market cap of $1.13 billion, a P/E ratio of -12.18 and a beta of 1.02.

Insider Activity

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $335,787.06. Following the transaction, the chief executive officer now directly owns 1,036,523 shares of the company’s stock, valued at approximately $28,514,747.73. This trade represents a 1.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 2,000 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 129,195 shares of company stock worth $3,581,772. 29.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of large investors have recently bought and sold shares of ELVN. Quest Partners LLC increased its stake in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after acquiring an additional 3,559 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics during the third quarter worth about $256,000. Verition Fund Management LLC bought a new position in Enliven Therapeutics during the 3rd quarter valued at approximately $271,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $322,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.